METTL16/ALKBH5/FTO/Reader Inhibitors

About Chemestmed

Chemestmed is a preclinical-stage biotech pioneering a novel approach to drug discovery by targeting the epitranscriptome, specifically the m⁶A RNA modification pathway. Its core platform focuses on developing small-molecule activators of the METTL3/METTL14 methyltransferase complex to restore healthy RNA methylation levels, with applications in Parkinson's disease, anxiety, type 2 diabetes, and obesity. The company, led by a team with deep scientific and pharmaceutical industry expertise, is also developing inhibitors against other epitranscriptomic targets like METTL16 and FTO for oncology. Operating as a private, pre-revenue entity, Chemestmed aims to address previously undruggable pathways in major disease areas.

Therapeutic Areas